Nearly 10 billion inhalation preparations market has been divided by these five enterprises

According to the test data of Zhongkang CMH data, the scale of respiratory system drug use in China reached 137.2 billion yuan, of which the market of inhalation preparations is on the rise In 2016, the scale of market drug use was 9.3 billion yuan, an increase of 22.4% over 2015 Looking at the categories and manufacturers of the market, we can find that the market concentration is relatively high Top 5 enterprises account for 98.3% of the market share With the rapid development of economy and the continuous acceleration of industrialization, air pollution and the change of people's life style, the prevalence of respiratory diseases such as asthma and COPD in China is increasing rapidly There are about 70 million patients with asthma and COPD in China Inhalation preparation disperses the drug into a mist by means of the projective agent, compressed air or special device, forming a drug aerosol, so that the drug can reach the action site directly Compared with the oral route, inhalation preparation can avoid the first pass effect of liver It has the advantages of small stimulation, convenient use, good compliance of patients, small side effects and suitable for long-term treatment The World Health Organization has recommended it as the first choice treatment for respiratory diseases such as asthma and chronic obstructive pulmonary disease, which has a broad market development prospect in China Nearly 10 billion market scale, with an annual growth of 22.4% According to the monitoring data of Zhongkang CMH, in 2016, the scale of respiratory system drugs in China reached 137.2 billion yuan, of which 69% were oral drugs, 20% were injection drugs, and only 7% were inhalation drugs In recent years, the market of inhaled respiratory drugs has been on the rise In 2016, the market drug use scale was 9.3 billion yuan, an increase of 22.4% compared with 2015 At present, inhaled preparations mainly include corticosteroids, β - adrenergic receptor agonists, M-cholinergic receptor antagonists and compound preparations The proportion of corticosteroids in inhalation preparations increased year by year, reaching 47.8% in 2016, followed by β - receptor agonists / corticosteroids, accounting for 26.8%
Inhaled glucocorticoids are suitable for long-term treatment of bronchial asthma, which can avoid all kinds of adverse reactions caused by systemic use of glucocorticoids At present, budesonide, fluticasone, beclomethasone, etc are mainly used clinically; β - adrenergic receptor agonists mainly include formoterol, salbutamol, terbutaline, etc.; anticholinergic drugs are used in the treatment of asthma and COPD The mask plays an important role, mainly including ipratropium bromide, tiotropium bromide, etc.; β receptor agonists / corticosteroids are mainly salmeterol of GSK and budesonide fomotol of AstraZeneca, which are the most commonly used compound dosage forms in clinical The market concentration is high, the market share of top 5 products accounted for 80% of the total market share of top 5 products of inhalation preparations in 2016 was 84.3%, and the market concentration is high In terms of single product, budesonide is the largest inhaler in sales, with a market share of 45% Currently, there are three kinds of inhaler suspension, powder inhaler and aerosol in the market, among which the sales of inhaler suspension is the largest and exclusive for AstraZeneca Glucocorticoids are the most effective anti-inflammatory drugs, long-term continuous inhalation of hormone drugs is one of the treatment methods for recurrent asthma For the patients with poor single treatment, the combination of salmeterol, ticasone and budesonide, formoterol are suitable for long-term asthma control drugs, and their development is relatively rapid in recent years Tiotropium bromide is the first long-acting anticholinergic drug, which plays an important role in the maintenance treatment of COPD It was listed in China in 2006 At present, two major domestic manufacturers are bringer Ingelheim and Zhengda Tianqing Market share of top 5 inhaled preparations: foreign funded enterprises accounted for 98.3% of the market share of top 5 inhaled preparations manufacturers in 2016, with a very high market concentration The first three are all foreign-funded enterprises, accounting for 95%, respectively AstraZeneca (57.1%), GlaxoSmithKline (24.4%) and bringer Ingelheim (13.6%) Then two domestic enterprises, Zhengda Tianqing (2.6%) and Lunan Pharmaceutical (0.5%), have a relatively small market share (3.1%)
In recent years, the proportion of AstraZeneca in the market of inhalation preparations has gradually expanded, and budesonide suspension for inhalation (Pulmicort) has contributed 70% of its sales, which belongs to the category with an annual sales volume of more than 1 billion; the second is budesonide formoterol powder inhalation (xinbic DUBAO); in addition, it also owns tebuconan Varieties of inhaled preparations such as talin, formoterol, etc In recent years, GlaxoSmithKline ranked second in the market share of inhalation preparations is in a declining trend The main varieties of inhalation preparations are salmeterol (Seretide), varieties with an annual sales volume of more than 1 billion, salbutamol (Ventolin) and fluticasone (vasopressin), etc The main varieties of Boehringer Ingelheim are ipratropium bromide (Aiquanle), tiotropium bromide (sriva) and Corbet, with annual sales of over 100 million The market share of the two domestic manufacturers is relatively small Zhengda Tianqing is mainly tiotropium bromide, with an annual sales volume of over 100 million and increasing year by year, while Lunan pharmaceutical is budesonide In general, the production process and technology requirements of inhalation preparations are relatively high, and domestic enterprises start slowly At present, foreign-funded enterprises have a greater advantage in most inhalation preparations Market Competition pattern of top 5 inhalers